L&C BIOLTD Balance Sheet Health
Financial Health criteria checks 3/6
L&C BIOLTD has a total shareholder equity of ₩157.5B and total debt of ₩81.0B, which brings its debt-to-equity ratio to 51.4%. Its total assets and total liabilities are ₩264.6B and ₩107.1B respectively. L&C BIOLTD's EBIT is ₩7.3B making its interest coverage ratio 1.6. It has cash and short-term investments of ₩52.4B.
Key information
51.4%
Debt to equity ratio
₩81.00b
Debt
Interest coverage ratio | 1.6x |
Cash | ₩52.43b |
Equity | ₩157.51b |
Total liabilities | ₩107.13b |
Total assets | ₩264.64b |
Recent financial health updates
Recent updates
L&C Bio's (KOSDAQ:290650) Performance Raises Some Questions
Mar 27Does L&C Bio (KOSDAQ:290650) Deserve A Spot On Your Watchlist?
Apr 20L&C Bio's (KOSDAQ:290650) Earnings Are Of Questionable Quality
Apr 01Is L&C Bio (KOSDAQ:290650) A Risky Investment?
Mar 02Announcing: L&C Bio (KOSDAQ:290650) Stock Increased An Energizing 163% In The Last Year
Feb 03What Is The Ownership Structure Like For L&C Bio Co., Ltd (KOSDAQ:290650)?
Jan 04Should You Be Excited About L&C Bio Co., Ltd's (KOSDAQ:290650) 16% Return On Equity?
Dec 08Financial Position Analysis
Short Term Liabilities: A290650's short term assets (₩124.5B) exceed its short term liabilities (₩103.9B).
Long Term Liabilities: A290650's short term assets (₩124.5B) exceed its long term liabilities (₩3.2B).
Debt to Equity History and Analysis
Debt Level: A290650's net debt to equity ratio (18.1%) is considered satisfactory.
Reducing Debt: A290650's debt to equity ratio has increased from 1.8% to 51.4% over the past 5 years.
Debt Coverage: A290650's operating cash flow is negative, therefore debt is not well covered.
Interest Coverage: A290650's interest payments on its debt are not well covered by EBIT (1.6x coverage).